Scarica l'app Stockscreener
28.08
1.65%
-0.47
Dopo l'orario di chiusura:
28.08
Avalyn Pharma Inc Borsa (AVLN) Ultime notizie
State Street Corp Makes New $10.50 Million Investment in Avalyn Pharma Inc. $AVLN - MarketBeat
Avalyn Pharma Inc. Stock Price Prediction: Today, Tomorrow, Next Week (AVLN) - Traders Union
Avalyn Pharma (NASDAQ:AVLN) Stock Price Down 9.2%Here's Why - MarketBeat
Avalyn Pharma (AVLN) Following AP02 Phase 1 Data Is Its Valuation Too Pricey - Yahoo Finance
Live Avalyn Pharma Inc. (AVLN) Technical Analysis - Traders Union
Avalyn Publishes Phase 1 Data Highlighting AP02’s Lung-Targeted Delivery and Encouraging Safety Profile - Stock Titan
Avalyn Pharma Inc.(NasdaqGS: AVLN) added to S&P Pharmaceuticals Select Industry Index - marketscreener.com
Avalyn Pharma Inc.(NasdaqGS: AVLN) added to S&P Global BMI Index - marketscreener.com
Avalyn Pharma (NASDAQ:AVLN) Cut to "Sell" at Wall Street Zen - MarketBeat
Avalyn Pharma (NASDAQ:AVLN) Shares Down 4.4%Here's What Happened - MarketBeat
Avalyn Pharma (NASDAQ: AVLN) Appoints Robert Meyer to Board with 31,182-Share Stock Option - Kalkine Media
Avalyn Pharma appoints former FDA official to board By Investing.com - Investing.com Canada
Avalyn Pharma appoints former FDA official to board - Investing.com
Avalyn Pharma (AVLN) adds ex-FDA leader to its board - Stock Titan
A former FDA leader with 25 years’ experience joins Avalyn’s board - Stock Titan
Avalyn Appoints Robert J. Meyer, MD, to its Board of Directors - finance.yahoo.com
Avalyn Pharma (NASDAQ:AVLN) Shares Gap UpShould You Buy? - MarketBeat
Avalyn Pharma (NASDAQ:AVLN) Trading Up 6.8%Time to Buy? - MarketBeat
Avalyn Pharma (NASDAQ:AVLN) Rating Increased to Hold at Wall Street Zen - MarketBeat
Bank of New York Mellon Corp Acquires New Shares in Avalyn Pharma Inc. $AVLN - MarketBeat
Avalyn Pharma presents AP01 lung distribution modeling data By Investing.com - Investing.com Canada
Avalyn Pharma presents AP01 lung distribution modeling data - investing.com
People with lung scarring are willing to travel for trials, Avalyn survey finds - Stock Titan
Avalyn Pharma Inc. (NASDAQ:AVLN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Avalyn Pharma Inc. Common Stock (NASDAQ: AVLN) Stock Price, News & Analysis - Kalkine
AVLN Options Overview History for Avalyn Pharma Stock - Barchart.com
Braidwell LP Invests $26.38 Million in Avalyn Pharma Inc. $AVLN - MarketBeat
Montanova Capital LLC Takes Position in Avalyn Pharma Inc. $AVLN - MarketBeat
Avalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026 - Barchart.com
Avalyn will present a model of how an inhaled treatment may spread through the lungs - Stock Titan
AVLN Options Volatility — NASDAQ:AVLN - TradingView
AVLN Options Chain — NASDAQ:AVLN - TradingView
Avalyn Pharma (NASDAQ:AVLN) Sets New 1-Year HighHere's Why - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Avalyn Pharma (NASDAQ:AVLN) Cut to Sell at Wall Street Zen - MarketBeat
Novo Holdings A/S (AVLN) discloses 8.8% beneficial stake in Avalyn Pharma - Stock Titan
Jefferies Maintains Avalyn Pharma(AVLN.US) With Buy Rating, Maintains Target Price $52 - Moomoo
Morgan Stanley Maintains Avalyn Pharma(AVLN.US) With Buy Rating, Raises Target Price to $57 - Moomoo
Avalyn Pharma (NASDAQ:AVLN) Hits New 52-Week High Following Better-Than-Expected Earnings - MarketBeat
AVLN SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Avalyn Pharma Q2 Results: EPS misses estimate by 22.64% - scanx.trade
Avalyn Pharma (NASDAQ:AVLN) Trading Up 8.2% Following Better-Than-Expected Earnings - MarketBeat
Form 8K Avalyn Pharma Inc. For: 12 August By Investing.com - Investing.com Nigeria
Avalyn Pharma Inc. Q2 2026: Net loss $(28.9M), EPS $(0.98) — 10-Q Summary - TradingView
Avalyn Pharma's Q2 Net Loss Widens - Yahoo Finance
Avalyn: Q2 Earnings Snapshot - AOL.com
AVLN: Completed Phase 2b trial enrollment and secured $413.5M cash runway into 2029 - TradingView
AVLN: Net loss widened on higher R&D spend; IPO proceeds extend cash runway into 2029 - TradingView
Avalyn Pharma reports Q2 2026 net loss $28.9M; cash $413.5M, runway into 2029 - TradingView
Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights - marketscreener.com
Avalyn Pharma Inc. (NASDAQ:AVLN) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Avalyn Pharma (AVLN): Norwest Venture Partners discloses 5.1% ownership stake - Stock Titan
Biotech Stocks At 52-Week HighsHALO +20% On Q2 Results, FENC, AVLN, AMLX, CHE - RTTNews
Avalyn Pharma Inc.common stock (AVLN) Stock Price, News, Quote & History - FinancialContent
Avalyn Pharma (NASDAQ:AVLN) Reaches New 52-Week HighTime to Buy? - MarketBeat
3.06%
2.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):